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Abstract
Background: In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA,
Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence.
Due to a lack of clinical evidence and expertise, managing these AEs can be challenging for patients and physicians
alike. In the absence of evidence, consensus recommendations from physicians experienced in using pirfenidone to
treat IPF are beneficial.
Methods: Using a modified Delphi process, expert recommendations were developed by a panel of physicians
experienced with using pirfenidone for IPF. Over three iterations, panelists developed and refined a series of
statements on the use of pirfenidone in IPF. Their agreement on each statement was ranked using a Likert scale.
Results: A panel of 12 physicians participated and developed a total of 286 statements on dosing and
administration, special populations, drug-drug interactions, laboratory analysis, warnings and precautions, and AE
management. Expert recommendations were achieved with regard to slower initial titrations and slower titrations
for AEs, dosing with meal(s) or substantial meals, and adding other prescribed pharmacological agents for AEs.
Conclusion: Until there is further clinical evidence, the resulting consensus recommendations are intended to
provide direction on the practical management of IPF with pirfenidone, by encompassing a broad experience from
the real world to complement data gleaned from clinical trials.
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Background
Idiopathic pulmonary fibrosis (IPF) is a rare disease
characterized by a variable decline in lung function, due
to progressive scarring of lung tissue [1]. The disease occurs primarily in middle-aged to older individuals [2, 3].
The incidence and prevalence rates of IPF have been rising, due to the aging population of the United States
(US) [2, 3]. Globally, mortality with IPF appears to be increasing as well, however, variations exist in mortality
trends and rates between different countries [4, 5].
While the cause of IPF is currently unknown, it is hypothesized that aging and genetic factors play a role in
disease development [2, 3]. Effective treatment options
for IPF are limited, with only two anti-fibrotic medications currently approved to treat the disease in the US
[6].
Pirfenidone (Esbriet®, Genentech USA, Inc. South San
Francisco, CA.) is an orally administered anti-fibrotic indicated for the treatment of IPF [7]. It was approved in
the United States in 2014 based on data from the Phase
III ASCEND trial, supported by two other Phase III trials, CAPACITY 1 and 2 [8–10]. Like other anti-fibrotics,
pirfenidone may cause adverse events (AEs) ranging
from mild GI (gastrointestinal) side effects to severe
drug reactions. Discontinuation rates with pirfenidone as
a result of AEs are as high as 30% [11, 12]. Furthermore,
recent data from a pooled meta-analysis of Phase II and
Phase III studies show that patients who remain on pirfenidone for 120 weeks or more have a clinically significant reduction in all mortality outcomes examined, thus
suggesting the key to success with pirfenidone is to get
the patients on treatment and maintain them on their
treatment [13]. Therefore, when using anti-fibrotic medications such as pirfenidone to manage patients with
IPF, education to define treatment expectations is integral to enable the prevention and effective management
of AEs. This is also essential to facilitate and improve
adherence to therapy [14]. Due to limited clinical experience and a narrow base of published recommendations,
mitigating and preventing AEs with pirfenidone is challenging, and best practice strategies often go undefined.
Pivotal trial data and prescribing information are a useful source of efficacy and safety data. Yet, these sources
do not incorporate real-world or experiential learning
with regard to pirfenidone and may neglect detailed information on AE management as well as the nuances of
dose titration. Recent Delphi recommendations have
been published for other therapies and anti-fibrotics that
are used to treat IPF [15–17]. While there are a few published resources with expert opinion and real-world evidence on the topic of managing pirfenidone-associated
AEs, these recommendations may be incomplete and
can be further developed to provide clarity. Both Costabel et al. and Lancaster et al. previously reported AE
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management of pirfenidone, however, these results
grouped recommendations for a broad range of AEs and
do not contain specific directions for the most common
AEs reported with pirfenidone [18, 19].
Despite a scarcity of clinical and evidence-based data
or guidance, it is critical for physicians treating IPF to
adequately address pirfenidone-related AEs and manage
other specific circumstances. The expert advice from
physicians experienced in the treatment of IPF with pirfenidone may benefit other physicians and their patients.
The Delphi method is a proven methodology for gathering and compiling consensus advice when evidence is
scarce. This Delphi study thus intends to provide consensus recommendations for the management of IPF
with pirfenidone based on the current practice in the
US. The expert panel in this study comprised of USbased physicians who routinely manage treatmentrelated AEs associated with pirfenidone.

Methods
Sponsored and funded via Genetech (see full funding
disclosure), a modified Delphi process was used to develop the consensus statements contained within this report. The Delphi process was originally described by
Delbecq and colleagues, and is a proven methodology to
gain consensus advice on a topic of interest [20–24].
The first and the senior author (FFR), and second authors (ZS) and (SDN) served as study moderators and
recruiters of the Delphi panelists. The target Delphi
panel size was 15–20 members, where US investigators
from the ASCEND and CAPACITY pivotal trials of pirfenidone were invited to participate. Following these recruitment efforts, a search of recent published literature
on pirfenidone (5-year period) was conducted to gather
a list of potential panelists. All panelists who actively
participated (defined as completing and returning at
least 2 out of 3 questionnaires including the final questionnaire and reviewing draft and final manuscripts) in
our Delphi study were included as coauthors, per the
International Committee of Medical Journal Editors criteria for authorship.
Via a series of 3 questionnaires, our modified Delphi
study established statements based on the prescribing information of pirfenidone, clinical trial evidence, and the
panelists’ own experience and knowledge. The modified
Delphi procedure has been previously described [25, 26]
and key steps in the process are outlined as follows
(Fig. 1):
1. Based on published literature, an initial
questionnaire was developed by moderators (FFR,
ZS and SDN) and distributed to the panel via an
online survey platform [4, 8–10]. In this initial
questionnaire panelists responded to multiple open-
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Fig. 1 The Delphi process used in the study

ended statements relevant to the use of pirfenidone,
independently of one another.
2. Upon receipt of responses to the initial
questionnaire, the moderators summarized the
feedback and developed a second questionnaire
spreadsheet that incorporated the initial statements
and additional statements added by the panelists.
3. Panelists then independently voted on the second
questionnaire and ranked each statement on a
numeric Likert scale ranging from − 3 (strongly
disagree) to + 3 (strongly agree) to establish
preliminary consensus. The second questionnaire
was circulated to the Delphi panelists by email and
was also completed on an electronic survey platform.
4. The moderators then aggregated the responses to
the second questionnaire and developed a final
questionnaire as well as a feedback report for the

Delphi panelists. The third and final questionnaire
requested panelists to rate each statement on a
numeric Likert scale ranging from − 5 (strongly
disagree) to + 5 (strongly agree) to improve
discriminant ability.
5. Finally, the results of the final questionnaire were
aggregated into a summary spreadsheet and
circulated to the panelists for review and comment.
The anonymity of the panelists was critical throughout the Delphi study, thus ensuring that no bias was
induced by influential clinicians. Panelists were encouraged to provide feedback on the validity, specificity, and content of the items under consideration.
All comments were incorporated verbatim and anonymity was maintained in all three rounds of the
questionnaires.
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Fig. 2 The Likert scale used in the final stage of the Delphi process. For the following Delphi Consensus Figs. 3, 4, 5, 6, 7, 8, 9, 10, statements with
a consensus for are bolded; statements with consensus against are shown with a grey background

Consensus was defined when the mean rating from
the panelists was ≥2.5 or ≤ − 2.5, on the Likert scale used
in the final questionnaire (Fig. 2), with a standard deviation that did not cross zero [25]. Recommendations
with a mean rating absolute value ≥4.0 were defined as
strong. Consensus was not defined for questions answered with a time period rather than the Likert scale.

Results
In total, 12 physicians joined the Delphi panel, consisting of
members practicing in academic (n = 10), hospital (n = 3),
and Veterans Administration (n = 1) settings (some panelists practice across multiple care settings). Their collective
experience with IPF was 17.6 ± 7.1(mean ± SD) years; treating 23.3 ± 11.1 (mean ± SD) patients with IPF per month
and prescribing pirfenidone to 50.4 ± 34.6 (mean ± SD) patients. Percentages of practices devoted to patients with IPF
ranged from 5 to 85% with an average of ~ 40% of their
practices being devoted to treating IPF. All 12 panelists participated actively in the Delphi process. The final Delphi
questionnaire was divided into 5 topics including 286 statements. All statements and the results of the final questionnaire are shown in Figs. 3, 4, 5, 6, 7, 8, 9.
Panelists strongly recommended that patients who have
missed a dose of pirfenidone skip the missed dose and
strongly recommended against taking two doses at the
same time to make up for the missed dose. For treatment
interruptions of less than 14 days, doses should be slowly
re-titrated if mild/moderate or severe AEs occur. A slower
titration scheme should be considered with respect to patient preference and AEs. Dose escalations can be made
every 2 weeks rather than every week for elderly or frail
patients or patients experiencing side effects. Panelists favorably ranked increasing doses over a longer time period
(either every 2 or 3 weeks) or allowing the patient to do a
step-wise approach (i.e. increase the evening dose first
[when symptoms may be less] before increasing the morning dose as the optimal dosing titration scheme for patients experiencing side effects) (Fig. 3).

Panelists reached a consensus that pirfenidone should
be permanently discontinued if a patient exhibits > 3 but
≤5 × upper limit of normal (ULN) alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) accompanied by symptoms or hyperbilirubinemia. These
patients should not be re-challenged. Their liver abnormalities should be evaluated for other causes. Concomitant medications should be examined and evaluated for
possible contribution to the liver impairment. Moreover,
if a patient exhibits > 5 × ULN ALT and/or AST, pirfenidone should be permanently discontinued, the patient
should not be re-challenged with pirfenidone, and their
liver abnormalities should be evaluated for other causes.
These patients may be referred to hepatology (Fig. 4).
The panelists strongly favored not adjusting doses for
elderly populations, however, a modest consensus was
obtained on having a lower threshold to down-titrate
these patients, or to slow their dose escalation compared
to younger subjects. Smokers should be instructed to
stop smoking, and smoking cessation contracts and education should be administered. The panel came to agreement to monitor patients with hepatic impairment every
2 weeks initially then monitor monthly continuously. For
patients with renal impairment, panelists strongly
favored following the guidance in the package insert
(Fig. 5).
The panelists were in consensus and strongly disagreed that no laboratory tests are necessary to initiate
treatment with pirfenidone. They favored ordering
complete blood count (CBC) and comprehensive metabolic panel (CMP). Liver function tests (LFTs) should be
considered monthly, and blood tests should be followed
frequently if a patient has liver disease (Fig. 6a).
Reinforcement (more strongly than usual) that the patient notify the prescribing physician of any potential
side effects was strongly suggested (Fig. 6b).
The group recommended following the package insert
for guidance around CYP1A2 inhibitors with respect to
dose modifications due to drug interactions and suggested seeking alternatives in patients being treated with
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Fig. 3 Dosing and Administration. Statements with a consensus for are bolded; statements with consensus against are shown with a grey background

pirfenidone. Nintedanib should be considered if CYP1A2
inhibitors are necessary (Fig. 7).
With specific regard to GI side effects, panelists favored coupling doses of pirfenidone with full meals, not
snacks; increasing doses over longer periods of time
(every 2 or 3 weeks); and allowing patients to do a stepwise approach that increases the evening dose first
(when symptoms may be less) before increasing the
morning dose (Fig. 8). Panelists strongly recommend patients take pirfenidone with a substantial meal. Agreement was also achieved to take the drug before eating,
or toward the end of their meal, or to spread capsules
over the course of the meal. No consensus was obtained
on the specific make up of meals. The causes of GI AEs
should be assessed for other causes beyond treatment
with pirfenidone (Fig. 9).

The panelists provided several consensus recommendations for management of common AEs.
Figure 10a-n illustrate the strength of these
recommendations.

Rash

In a patient who experiences rash, it is important to assess for other causes of rash. Ensure the use of sun protection (e.g. protective clothing, sunscreen, long sleeves,
and hats) as well as reduce the amount of sun exposure.
Referral to a dermatologist is not recommended for rash.
A drug interruption/holiday may be useful in these
patients. Pirfenidone should be discontinued if severe,
persistent rash occurs and treatment with another antifibrotic should be considered.
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Fig. 4 Liver Abnormalities. Statements with a consensus for are bolded; statements with consensus against are shown with a grey background

Upper respiratory tract infections (URTI)

Dizziness

URTI should be monitored and treated with supportive
care, over the counter (OTC) medications and/or antibiotics. Patients with URTI can remain at their prescribed
dose of pirfenidone. It was not recommended to discontinue pirfenidone nor start another anti-fibrotic medication for patients with URTI.

Dizziness should be evaluated for other causes. Blood
tests should be ordered and levels of magnesium
(Mg++) should be checked (prescribe Mg++ if deficient).
Blood pressure should be monitored, and an echocardiogram can be performed. If blood pressure is low, reduce
blood pressure medications. Encourage dizzy patients to

Fig. 5 Special Populations. Statements with a consensus for are bolded; statements with consensus against are shown with a grey background
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Fig. 6 a Laboratory Monitoring and Testing. b Laboratory Monitoring and Testing (Hepatic or Renal Impairment). Statements with a consensus
for are bolded; statements with consensus against are shown with a grey background
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Fig. 7 Dosing Modification due to Drug Interactions. Statements with a consensus for are bolded; statements with consensus against are shown
with a grey background

stay well hydrated. It was not recommended to discontinue pirfenidone nor start another anti-fibrotic medication for patients experiencing dizziness.
Insomnia

Assess for other causes of insomnia beyond the use of
pirfenidone. Counsel the patient on sleep hygiene, timing
on dose in relation to bedtime, and advise them to avoid
caffeine. Referral to the patient’s primary care physician
(PCP) is recommended. It was not recommended to discontinue pirfenidone nor start another anti-fibrotic medication for patients experiencing insomnia.
Arthralgia

Arthralgia should be assessed for other causes and
managed. Referral to the patient’s PCP is recommended for vitamin D level and bone density testing.
A connective tissue work up should be performed

prior to initializing therapy. Exercise should be
encouraged. Patients experiencing arthralgia should
remain at their prescribed dose of pirfenidone. It was
not recommended to discontinue pirfenidone nor
start another anti-fibrotic medication for patients
experiencing arthralgia.

Fatigue

Other causes of fatigue should be ruled out. Counsel
patients on sleep medicine and hygiene as well as
prescribe pulmonary rehab. Thyroid and testosterone
levels should be checked, and a complete blood count
should be performed. Patients should be reassured
after they are evaluated. Dose reductions are suggested in patients with fatigue. Pirfenidone should be
discontinued if severe fatigue occurs and treatment
with another anti-fibrotic can be considered.

Fig. 8 Dosing Modification due to Side Effects. Statements with a consensus for are bolded; statements with consensus against are shown with a
grey background
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Fig. 9 Gastrointestinal Adverse Events. Statements with a consensus for are bolded; statements with consensus against are shown with a
grey background

Abdominal pain

Patients who develop abdominal pain should be ensured/advised to take their dose with food/meal. Abdominal pain should be assessed for other causes not
related to pirfenidone. A PPI can be prescribed to these
patients. Dose reductions and drug holidays are suggested in patients with abdominal pain. Pirfenidone
should be discontinued if severe abdominal pain occurs
and treatment with other anti-fibrotics can be considered.
Anorexia

Discussing eating habits, increasing the amount of small
portioned meals, and adding oral supplementation for
patients experiencing anorexia is recommended. Dose

reductions and drug holidays are suggested in patients
with anorexia. Pirfenidone should be discontinued if
after exhausting all remedies severe anorexia occurs and
treatment with other anti-fibrotics can be considered.

Diarrhea

Patients who experience diarrhea should be ensured/advised to take their dose with food/meal. Loperamide and
atropine/diphenoxylate can be prescribed to these patients and dose reductions and drug holidays are suggested. After exhaustion of all remedies, pirfenidone
could be discontinued if severe diarrhea occurs and
treatment with another anti-fibrotic can be considered.
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(See figure on previous page.)
Fig. 10 a Nausea (reported incidence: 36%). b Rash (reported incidence: 30%). c Abdominal pain (reported incidence: 24%); includes upper
abdominal pain, abdominal distension, and stomach discomfort. d Upper respiratory tract infection (reported incidence: 27%). e Diarrhoea
(reported incidence: 26%). f Fatigue (reported incidence: 26%). g Dyspepsia (reported incidence: 19%). h Dizziness (reported incidence: 18%). i
Vomiting (reported incidence: 13%). j Anorexia (reported incidence: 13%). k Gastroesophageal Reflux Disease (reported incidence: 11%). l
Insomnia (reported incidence: 10%). m Weight decreased (reported incidence: 10%). n Arthralgia (reported incidence: 10%). Statements with a
consensus for are bolded; statements with consensus against are shown with a grey background

Dyspepsia

Patients who experience diarrhea should be advised to
take their dose with a meal and advised to spread their
pills out over the course of the meal. Proton pump inhibitors (PPI) and antacids like Maalox®, and TUMS®
may be prescribed. Dose reductions are recommended
for patients with dyspepsia. After exhausting all remedies, pirfenidone should be discontinued if severe dyspepsia occurs and treatment with another anti-fibrotic can
be considered.
Gastro-esophageal reflux disease (GERD)

Education on diet and positional approaches, as well as
ensuring that patients take their dose with meals is recommended for patients with GERD. PPIs and H2 (histamine 2) blockers should be prescribed for GERD with
dose reductions and drug holidays as additional suggestions. After all remedies are exhausted, pirfenidone
should be discontinued if severe GERD occurs and treatment with another anti-fibrotic can be considered.
Nausea

Patients who experience nausea should be advised to
take their dose with food and advised to take their pills
separately throughout the duration of their meal. Prescribe/add 5-Hydroxytryptamine type 3 (5HT3) receptor
antagonists such as ondansetron for patients with nausea, with dose reductions and drug holidays as further
suggestions. After all remedies are exhausted, pirfenidone should be discontinued if severe nausea occurs and
treatment with another anti-fibrotic can be considered.
Vomiting

PPIs and 5HT3 receptor antagonists are recommended for
patients who experience vomiting. Dose reductions and
drug holidays are suggested and pirfenidone should be discontinued if severe vomiting occurs. In such situations,
treatment with another anti-fibrotic can be considered.
Weight loss

Encouraging eating, discussing eating habits, and increasing the frequency and size of meals are recommended for patients with decreased weight. Fatty meals
are recommended as well as dietary supplements. Dose
reductions are recommended for patients with decreased
weight. Pirfenidone could be discontinued if after

exhausting all remedies severe weight loss occurs, and
treatment with another anti-fibrotic can be considered.

Discussion
At a time where there is a lack of evidence-based realworld data, this report is intended to aid physicians who
use pirfenidone in managing patients with IPF. The goal
of this report is to provide expert guidance for quality
treatment and care relating to pirfenidone-associated
AEs and interruptions in therapy. The key to success
with pirfenidone is to not only start patients on therapy
early, but to maintain them on therapy as evidenced by
improved mortality in treatment adherent patients [13].
With discontinuation rates of approximately 30%, any
guidance that facilitates patients staying on treatment
may result in improved outcomes, even at lower more
tolerable doses [27]. The consensus recommendations
contained within this report were developed by a panel
of physicians experienced with pirfenidone and IPF
using a modified Delphi methodology. The Delphi
process developed a total of 286 statements and the
panel reached consensus on 162 of those statements.
Our findings build on the consensus recommendations
published by Costabel et al. and Lancaster et al. and further provide guidance on the most common AEs associated with pirfenidone as opposed to developing
recommendations for groups of AEs as a whole [18, 19].
Strong consensus was achieved on several recommendations in our study. Panelists agreed that pirfenidone dosing titration schedules can be extended and modified
when AEs or concerns for AEs are an issue. Frequent
monitoring for abnormalities and coupling doses of pirfenidone with food were also suggested. Management
options, including palliative medications for the most
frequent AEs associated with pirfenidone are contained
within. This real-world methodology on how to use and
titrate pirfenidone provides very practical knowledge
that augments the prescribing information and the randomized control trial methodologies to translate useful
practical know-how for lesser experienced physicians.
For this study, the Delphi method was implemented
using electronic communications to gather and distribute
information. With this format, panelists were able to
complete the surveys without stringent time restrictions or
need for travel. All panelists’ opinions were weighed
equally, as the Delphi process uses a systematic, anonymous
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process that promotes open sharing of thoughts and beliefs
while making it difficult for any one panelist to dictate the
process. Electronic communications were utilized so as to
uphold the anonymous nature of the Delphi process.
Limitations

The Delphi process has several limitations [25, 26], lack
of a standardized consensus-defining criterion being one
of the drawbacks [28–30]. Given that the study is designed to elicit guidance when no strong evidence is
available, the process itself may not be statistically rigorous, and even if consensus is reached, there is no guarantee that the consensus answer is generalizable or
appropriate [28, 30, 31].
Bias can inadvertently be introduced during the
process of panel selection and the development of the
initial questionnaire, even though there are measures in
place to prevent it [23, 29]. Anonymity is an integral
component of the Delphi process, but this also means
lesser accountability of the panelists towards their responses, and generation of responses with insufficient or
minimal consideration [28]. Panelists with relatively less
experience in the field may have a voice disproportionate
to their familiarity with disease treatment, as less experienced panelists can vote against and effectively limit the
statistical weight of the standard methods suggested by
more experienced panelists. Due to the fact that the panelists were assembled for their diverse experiences with
pirfenidone and IPF, this issue is unlikely to have been
significant in this study and the manuscript aims to capture the broad spectrum of opinions [23].
In this study, the selection of US-based expert panelists was limited to ≤20 participants to help make the
process manageable as well as limit responses to therapeutic strategies not pertinent to the US. As a result, the
Delphi consensus may not represent global perspectives.
Additionally, the small sample size (N = 12) might indicate that certain important perspectives from a larger,
more representative population of US-based physicians
might have been missed in this study. By intentionally
selecting a panel of clinical researchers experienced with
the clinical trials for pirfenidone (as outlined in
Methods), most panelists may have some association
with Genentech beyond this Delphi study. Other potential stakeholders, such as patients, pharmacists, and
payers, were also not included, which might have further
limited the diversity of perspectives. Study parameters
stated above might have introduced biases in this paper,
though we hope that this is minimized by the Delphi
process and study focus area which is mostly concerned
about AE management and titration/use of medication
and not patient selection. In spite of the small sample
size, the panelists managed to achieve consensus on 57%
of the statements.
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Conclusion
In conclusion, the Delphi process was used to develop
expert consensus recommendations on the use of pirfenidone in managing patients with IPF to keep patients
on therapy and improve outcomes. The recommendations aim to provide useful guidance on appropriate clinical management of IPF with pirfenidone, encompassing
a broad experience from the real world than what has
been studied in the trials.
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